Abstracts tagged "psoriatic arthritis and rheumatoid arthritis (RA)"

Abstract Number: 59 • 2014 ACR/ARHP Annual Meeting
Assessing Dietary Habits in a Large Cohort of Rheumatoid Arthritis and Psoriatic Arthritis Patients: Results of the Spanish Imid Consortium
Maria López Lasanta¹, Jesús Tornero², Juan D. Cañete³, Antonio Fernandez Nebro⁴, Francisco Blanco⁵, Jesus Rodriguez⁶, Isidoro González-Alvaro⁷, Jordi Gratacós⁸, Joan Maymo⁹, Rubén Queiro¹⁰, Mercedes Alperi-López¹¹, Carlos Montilla-Morales¹², Benjamin Fernandez Gutierrez¹³, Juan Carlos Torre-Alonso¹⁴, Alejandro Olive¹⁵, Jose Javier Perez Venegas¹⁶, Hector Corominas¹⁷, Alba Erra¹⁸, Santiago Muñoz¹⁹, Carlos M. Gonzalez²⁰, Daniel Roig²¹, Gabriela Avila¹, Arnald Alonso¹, Toni Julia¹, Raül Tortosa¹, Andrés Garcia Montero²² and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Hospital Universitario Guadalajara, Guadalajara, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Regional Carlos Haya, Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain, ⁵Complejo Hospitalario Juan Canalejo, A Coruña, Spain, ⁶Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ⁷Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁸Hospital Parc Taulí, Sabadell, Spain, ⁹Rheumatology, Hospital del Mar, Barcelona, Spain, ¹⁰Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ¹¹Rheumatology Department, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹²H. de Salamanca, Salamanca, Spain, ¹³Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ¹⁴Rheumatology Department, H. Monte Naranco, Oviedo, Spain, ¹⁵Rheumatology Service, Germans Trias Pujol Hospital, Barcelona, Spain, ¹⁶Rheumatology Department, Hospital del SAS Jerez de la Frontera, Cadiz, Spain, ¹⁷Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ¹⁸Rheumatology Department, Hospital Sant Rafael, Barcelona, Spain, ¹⁹Rheumatology Department, Hospital Infanta Sofia, Madrid, Spain, ²⁰Rheumatology Department, Gregorio Marañon Hospital, Madrid, Spain, ²¹Rheumatology Service, Hospital Moisès Broggi,, Barcelona, Spain, ²²Banco Nacional de ADN, Salamanca, Spain
Background/Purpose: Rheumatoid arthritis (RA) and Psoriatic arthritis (PsA) are complex diseases of unknown etiology and its pathogenesis results from the combination of genetic susceptibility and…
Abstract Number: 184 • 2013 ACR/ARHP Annual Meeting
Are Physician Gender, Age and Clinical Experience Associated With Discrepancy In Global Disease Score In Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis? Data From The Nationwide Danbio Registry
Cecilie Lindstrom Egholm¹, Niels Steen Krogh², Lene Dreyer³, Torkell Ellingsen⁴, Bente Glintborg⁵, Marcin Kowalski⁶, Tove Lorenzen⁷, Ole Rintek Madsen⁸, Henrik Nordin^9,10, Claus Rasmussen¹¹ and Merete L. Hetland¹², ¹Regional Research Unit, Region Zealand, Roskilde, Denmark, ²ZiteLab ApS, Copenhagen, Denmark, ³Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ⁴Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, Denmark, ⁵Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁶Aalborg University Hospital, Aalborg, Denmark, ⁷Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁸Department of Rheumatology, Copenhagen University Hospital in Gentofte, Copenhagen, Denmark, ⁹Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Denmark, ¹⁰DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ¹¹Vendsyssel Teaching Hospital/Aalborg University, Hjoerring, Denmark, ¹²Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: A global estimate on a 100 mm Visual Analogue Scale (VAS) assessed by patients (PATGL) and physicians (DOCGL) is commonly used to measure disease…
Abstract Number: 2762 • 2013 ACR/ARHP Annual Meeting
Rheumatoid and Psoriatic Arthritis Are Not Associated With Higher Risk Of Incident Diabetes Mellitus
Susan Mathew¹, Xiaoqin Tang², H. Lester Kirchner³, Mary Chester M. Wasko⁴ and Androniki Bili¹, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Biostatistics, Geisinger Center for Health Research, Danville, PA, ³Geisinger Center for Health Research, Geisinger Health System, Danville, PA, ⁴West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic inflammatory conditions that are associated with increased risk of insulin resistance and cardiovascular disease…
Abstract Number: 2483 • 2013 ACR/ARHP Annual Meeting
Periarticular Bone Gain In Early Psoriatic Arthritis But Not In Rheumatoid Arthritis Following Anti-Rheumatic Treatment As Measured By Digital X-Ray Radiogrammetry
Agnes Szentpetery¹, Muhammad Haroon², Phil Gallagher³, Eric J. Heffernan⁴ and Oliver FitzGerald², ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Radiology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Hand bone loss is an early feature in both RA and PsA, but there is less data available on periarticular bone gain, in particular…
Abstract Number: 2041 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Women Exposed To Golimumab
Amy G. Lau¹, Michael Clark¹, Diane D. Harrison¹, Anja Geldhof², Riikka Nissinen² and Marilyn Sanders¹, ¹Janssen Research & Development, LLC., Horsham, PA, ²Janssen Biologics Europe, Leiden, Netherlands
Background/Purpose: Rheumatologic conditions and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing…
Abstract Number: 2042 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Women With Rheumatologic Conditions Exposed To Infliximab
Sirisha Kalari¹, Fredrik Granath², Chun-Yuan Guo¹, Diane D. Harrison¹, Gabriella Bröms², Anja Geldhof³, Riikka Nissinen³, Marilyn Sanders¹, Mika Gissler⁴, Lars Pedersen⁵, Henrik Toft Sorensen⁵ and Helle Kieler², ¹Janssen Research & Development, LLC., Horsham, PA, ²Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden, ³Janssen Biologics Europe, Leiden, Netherlands, ⁴Information Department, National Institute for Health and Welfare, Helsinki, Finland, ⁵Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: RA, AS, and PsA are approved indications for infliximab (IFX). In the US, IFX is a pregnancy Category B drug. For RA and some…
Abstract Number: 1417 • 2013 ACR/ARHP Annual Meeting
Lack Of Correlation Between Golimumab Exposure and Selected Safety Events Following Intravenous Or Subcutaneous Administration In An Integrated Analysis Of Phase 3 Data Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Or Ankylosing Spondylitis
Jocelyn H. Leu¹, Anna Beutler¹, Alan M. Mendelsohn², Sam Liao³, Hugh M. Davis¹, Honghui Zhou¹ and Zhenhua Xu¹, ¹Janssen Research & Development, LLC., Spring House, PA, ²Immunology, Janssen Research & Development, LLC., Spring House, PA, ³PharMax Research, Inc., Newport Beach, CA
Background/Purpose: For anti-TNFα agents, infections and malignancies are key safety concerns. It is unknown whether safety events are driven by peak (Cmax), trough (Cmin), average…
Abstract Number: 1398 • 2013 ACR/ARHP Annual Meeting
Comparison Of Atherogenicity Of Plasma From Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Beenish Hafiz¹, Iryna Voloshyna², Michael J. Littlefield², Steven E. Carsons³, Elise Belilos¹, Kristina Belostocki¹, Lois A. Bonetti⁴, Gary C. Rosenblum¹ and Allison B. Reiss², ¹Rheumatology, Winthrop University Hospital, Mineola, NY, ²Medicine, Winthrop University Hospital, Mineola, NY, ³Div of Rheumatology, Winthrop University Hospital, Mineola, NY, ⁴Rheum & Immun, Winthrop University Hospital, Mineola, NY
Background/Purpose: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are immune mediated inflammatory disorders linked to increased risk of cardiovascular disease (CVD), mostly due to accelerated…
Abstract Number: 1032 • 2013 ACR/ARHP Annual Meeting
Shared Decision-Making In The Choice Of Biologic Medication: The Patient Perspective
Susan C. Bolge¹, Helen Eldridge² and Michael P. Ingham¹, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Janssen Services, LLC., Titusville, NJ
Background/Purpose: There has been increasing focus on the importance of patients participating in the treatment decision-making process with their physicians. Previous research has demonstrated that…
Abstract Number: 384 • 2013 ACR/ARHP Annual Meeting
Carotid Artery Plaques Are Associated With Coronary Atherosclerosis In Patients With Inflammatory Joint Diseases Independent Of Several Cardiovascular Risk Calculators
Silvia Rollefstad¹, Eirik Ikdahl², Inge C. Olsen³, Tore K. Kvien^4,5, Anne S. Eirheim², Terje R. Pedersen^4,6 and Anne G. Semb², ¹Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Faculty of Medicine, University of Oslo, Oslo, Norway, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Centre of Preventive Medicine, Oslo University Hospital-Ullevaal, Oslo, Norway
Background/Purpose: Patients with rheumatoid arthritis (RA) and carotid plaque (CP) have been shown to have increased risk of future acute coronary syndrome. We have established…
Abstract Number: 385 • 2013 ACR/ARHP Annual Meeting
Systemic Inflammation In Patients With Inflammatory Joint Disease Does Not Influence Statin Dose Needed To Obtain Low Density Lipoprotein Cholesterol Goal In Cardiovascular Prevention
Silvia Rollefstad¹, Eirik Ikdahl², Tore K. Kvien^3,4, Terje R. Pedersen^4,5, Ingar Holme⁶ and Anne G. Semb², ¹Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Faculty of Medicine, University of Oslo, Oslo, Norway, ⁵Centre of Preventive Medicine, Oslo University Hospital-Ullevaal, Oslo, Norway, ⁶Department of biostatistics, epidemiology and health economics, Oslo University Hospital-Ullevaal, Oslo, Norway
Background/Purpose: There is a lipid paradox in rheumatoid arthritis (RA): despite low lipids influenced by systemic inflammation, there is an increased risk of cardiovascular (CV)…
Abstract Number: 346 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, a More Severe Disease Than Psoriatic Arthritis? A Comparison Of Disease Activity In Patients With Psoriatic Arthritis and Rheumatoid Arthritis From The Swedish Early Psoriatic Arthritis Registry (SwePsA) and The Swedish Rheumatology Registry For Early RA (SRR)
Gerd-Marie Alenius¹, Tomas Husmark², Elke Theander³, Per Larsson⁴, Mats Geijer⁵, Annika Teleman⁶ and Ulla R. C. Lindqvist⁷, ¹Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ²Department of Rheumatology, Falu Hospital, Falun, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Dept of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁵Skåne University Hospital, Lund, Center for Medical Imaging and Physiology, Lund, Sweden, ⁶Department of Rheumatology, Spenshult Hospital, Oskarstrom, Sweden, ⁷Department of Medical Sciences, Rheumatology, University Hospital, Uppsala university, Uppsala, Sweden
Background/Purpose: In clinical practise patients with psoriatic arthritis (PsA) seem to have milder disease expression compared with patients having rheumatoid arthritis (RA). Studies have, however,…
Abstract Number: 303 • 2013 ACR/ARHP Annual Meeting
Risk Of Cardiovascular Events In Patients With Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A General Population-Based Cohort Study
Alexis Ogdie¹, Yiding Yu², Kevin Haynes³, Samantha Maliha⁴, Thorvardur Love^5,6, Andrea Troxel⁷, Sean Hennessy⁸, David Margolis⁹, Stephen Kimmel¹⁰, Nehal N. Mehta¹¹, Hyon Choi^12,13 and Joel Gelfand¹⁴, ¹Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Medicine, Brigham and Women's Hospital, Boston, MA, ³Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁶Landspitali University Hospital, Reykjavik, Iceland, ⁷Biostatistics and Epidemiology, University of Pennsylvania., Philadelphia, PA, ⁸Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁹Dermatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ¹⁰Cardiology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ¹¹National Heart Lung Blood Institute, Cardiovascular and Pulmonary Division, NHLBI, National Institutes of Health, Bethesda, MD, ¹²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ¹³Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Dermatology and Epidemiology, University of Pennsylvania., Philadelphia, PA
Risk of Cardiovascular Events in Patients with Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A general population-based cohort studyBackground/Purpose: Psoriatic arthritis (PsA), psoriasis, and rheumatoid arthritis…
Abstract Number: 1334 • 2012 ACR/ARHP Annual Meeting
Intra-Articular Etanercept Treatment in Inflammatory Arthritis: A Randomized Double-Blind Placebo-Controlled Trial
Caroline J. Aalbers¹, Danielle M. Gerlag², Koen Vos¹, Gertjan Wolbink³, R. Landewe¹ and Paul P. Tak⁴, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁴Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: The use of intra-articular (IA) corticosteroid injections has been widely accepted as a therapy to control local inflammation. Studies on the use of IA…
Abstract Number: 1306 • 2012 ACR/ARHP Annual Meeting
How well Do Patients with Rheumatoid and Psoriatic Arthritis Tolerate Methotrexate? A Retrospective Review of Discontinuation Data From a Large UK Cohort
Calum T. Goudie¹, John D. Fitzpatrick¹, Anshuman P. Malaviya² and Andrew J. Ostor², ¹University of Cambridge Medical School, Cambridge, United Kingdom, ²Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom
Background/Purpose: Due to its efficacy and safety, methotrexate (MTX) has become the first-line disease-modifying drug for rheumatoid (RA) and psoriatic arthritis (PsA). Although deemed safe,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].